Noetik

The company brings together doctors, scientists, engineers, machine learning researchers, and computational biologists to discover precision cancer therapies.

Noetik uses advanced machine learning methods to discover and develop cancer immunotherapies.

Noetik announces a $50+ million collaboration and licensing agreement with GSK, giving the pharmaceutical company access to its OCTO-VC virtual cell foundation models for research into non-small cell lung cancer and colorectal cancer. GSK pays upfront capital fees plus annual licensing or subscription fees over five years. DCVC describes the agreement as TechBio's first substantial pure-play AI licensing deal, monetizing a biological foundation model as a scalable enterprise asset.

Jan 2026 · DCVCNews article

Noetik, a San Francisco-based AI-native biotech company, secures a $40 million Series A led by Polaris Partners, with the round oversubscribed. Existing investors DCVC, Zetta Venture Partners, Catalio Capital Management, and 11.2 Capital also support the financing, which funds expansion of Noetik’s spatial omics-based atlas of human cancer biology and training of its multimodal cancer foundation models.

Aug 2024 · Venture Capital JournalNews article

Noetik combines high-throughput spatial biology with self-supervised machine learning to classify tumors into therapeutically important immune subsets. Co-founders Ron Alfa and Jacob Rinaldi met in graduate school at Stanford and previously led efforts at Recursion. The company generates data at scale using spatial proteomics and transcriptomics platforms and recently closed an oversubscribed $14 million seed round led by DCVC.

Sep 2023 · GEN Genetic Engineering and Biotechnology NewsNews article

Noetik closes an oversubscribed $14 million seed financing led by DCVC, with participation from Zetta Venture Partners, 11.2 Capital, Catalio Capital Management, Epic Ventures, Intermountain Ventures, and others. The AI drug discovery company says the funding supports its spatial biology and machine learning platform for developing precision cancer immunotherapies and its plans to expand teams in machine learning, computational biology, and cancer immunology.

Sep 2023 · BioSpaceNews article